The Surge in Cell and Gene Therapies The Cell and Gene Therapy (CGT) sector is booming. Despite their scientific and clinical complexities, numerous advanced biological products are bringing notable treatment efficacy across multiple therapeutic areas based on their ability to deliver precision medicine. The Food and Drug Administration (FDA) predicts that by 2025 it will Read More …
Author: Alison James
Coulter Partners was very pleased to partner once again with Saniona (OMX: SANION), a clinical stage biopharmaceutical company focused on rare diseases, to secure the appointment of Jason A. Amello as Chief Financial Officer. Jason will be based in the U.S. and will support Saniona’s advancement of late-stage clinical trials with lead product candidate Tesomet in two rare eating disorders, hypothalamic obesity (HO) and Prader Willi Syndrome (PWS).
Coulter Partners was very pleased to partner recently with Sequana Medical NV, an innovator in the management of fluid overload in liver disease, malignant ascites and heart failure, to secure the appointment of Oliver Gödje, MD, PhD, as Chief Medical Officer.
Coulter Partners was delighted to partner recently with Optimapharm to secure the appointment of Dr. Andrew Copestake as Chief Executive Officer. Andrew joins Optimapharm’s executive management team following several months advising the company’s Board of Directors. Optimapharm is a contract research organization managing clinical trials on behalf of leading biotech, pharma and medical devices companies in 22 countries throughout Europe.
Coulter Partners recently talked to Tanja Dowe, Chief Executive Officer of Debiopharm Innovation Fund S.A. about digital disruption and talent in healthcare. “At CEO and C-suite level I look for authenticity, passion and values. Why is passion so important and perhaps more so in healthcare than in other industries? We need individuals who really want to solve some of the biggest societal problems – working together with end-users to improve global patient health.”
Coulter Partners recently talked to Cristina Duran, Chief Digital Health Officer in R&D for AstraZeneca about digital disruption and talent in healthcare. “In other industries such as banking or retail, a focus on customers has always been key to the success of digital transformation. For pharmaceuticals it is the same. We focus on the patient and listen to what they want or need. We put the patient at the centre, listening to feedback on their experience of a clinical trial, for instance – the good and the bad. We are working together with patients and physicians in all our disease areas of focus to clarify the potential health outcomes of different treatment pathways.”
Paul Sekhri, Chairman of the Board of Supervisory Directors: “We are thrilled to nominate Barbara Yanni and Mark Pykett as new members of the Board of Supervisory Directors. Their extensive experience and strong track record in pharmaceuticals and biotechnology in the US complements the existing expertise of our Board. Accordingly, they will further strengthen the Board’s ability to effectively oversee Pharming’s fast-growing global business activities, especially those in the increasingly important US market and I thank the team at Coulter Partners for their professional support in achieving these key nominations.”
The surge in fast growth private equity buy and build deals in healthcare services over the past few years has been exceptional and despite a brief COVID-19 related lull, seems to be continuing at pace. Bain and Company recently reported that the sector had the second-highest disclosed deal value globally after biopharma, despite this declining Read More …
“Medopad rebrands as Huma as it expands offerings and acquires AI and wearable tech startups.” –
Coulter Partners talked recently to Tamir Strauss, Head of Customer Solutions at Huma about digital disruption and talent in healthcare: “I think if regulators were able to combine the fundamental need to keep patients safe with the understanding that the world of software development is evolving rapidly, then innovation would explode across all areas of this industry.”
Coulter Partners was delighted to partner once again with Albumedix, the world leader in recombinant human albumin (rAlb), to secure the appointment of Gregor Kawaletz as Chief Commercial Officer, as of June 1st, 2020. This announcement follows the recent appointment of Jonas Skjødt Møller as Chief Executive Officer of Albumedix and is part of the company’s global growth strategy.